-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: The World Health Organization has declared that the novel coronavirus is the virus responsible for the 2019 (COVID-19) global outbreak of coronavirus disease that began in March 202 As of February 2022, COVID-19 has affected more than 429 million people worldwide and caused more than 9 million deat.
Background: The World Health Organization has declared that the novel coronavirus is the virus responsible for the 2019 (COVID-19) global outbreak of coronavirus disease that began in March 202 As of February 2022, COVID-19 has affected more than 429 million people worldwide and caused more than 9 million deat.
Assessment of persistent viral RNA shedding is one way to track recovery and long-term response to severe viral infecti.
Objective: To further understand the ongoing clinical care of hospitalized patients with COVID-19 and to explore disease mechanisms, we sought to determine the prevalence and risk factors of persistent viral RNA shedding and to assess its association with delirium, a major neurological complication of acute COVID-1 ) and 6-month mortality in hospitalized patients with COVID-1
Methods: We retrospectively assessed persistent viral shedding in Northwestern Medicine and Healthcare (NMHC) patients between March and August 202
Methods: We retrospectively assessed persistent viral shedding in Northwestern Medicine and Healthcare (NMHC) patients between March and August 202RESULTS: Among 2518 hospitalized patients with 2019-nCoV confirmed by reverse transcription polymerase chain reaction (RT-PCR), 959 patients had repeated 2019-nCoV RT-PCR at least 14 days after the first positive test (RT-PC.
RESULTS: Among 2518 hospitalized patients with 2019-nCoV confirmed by reverse transcription polymerase chain reaction (RT-PCR), 959 patients had repeated 2019-nCoV RT-PCR at least 14 days after the first positive test (RT-PC.
Table 1 Long-term (confirmed > 14 days) viral RNA shedding model
Table 2 Models of delirium (previously positive for confounding assessment methods) and acute brain dysfunction
Table 2 Models of delirium (previously positive for confounding assessment methods) and acute brain dysfunctionTable 3 Six-month mortality model
Table 3 Six-month mortality modelConclusions: Persistent viral shedding frequently occurs in hospitalized patients with COVID-19 and is associated with increased in-hospital delirium and 6-month mortali.
Conclusions: Persistent viral shedding frequently occurs in hospitalized patients with COVID-19 and is associated with increased in-hospital delirium and 6-month mortali.
Original source: Batra A, Clark JR, Kang AK, et .
Persistent viral RNA shedding of SARS-CoV-2 is associated with delirium incidence and six-month mortality in hospitalized COVID-19 patien.
Geroscience 2022 May 11 Persistent viral RNA shedding of SARS-CoV-2 is associated with delirium incidence and six-month mortality in hospitalized patien.
Leave a comment here
